Abstract
Parathyroid hormone (PTH) acts as an anabolic agent and is used for the treatment for osteoporosis. Daily or once-weekly self-administered subcutaneous injection of human PTH (1-34) (teriparatide) increased bone mineral density (BMD) compared to a placebo in post-menopausal osteoporotic patients. Recently, data have accumulated that collagen cross-link formation in bone affect bone strength. In fact, impaired enzymatic cross-linking and/or an increase in non-enzymatic cross-links, pentosidine, which is a surrogate marker of advanced glycation end products (AGEs) , in bone collagen have been proposed as a major cause of bone fragility in osteoporosis. We reported that teriparatide improves bone collagen cross-link formation, microarchitecture, and bone mass, resulting in the increase of bone strength (Saito M : Osteoporos Int 22 : 2373-83, 2011) . In this review, we described how teriparatide improve bone collagen cross-link formation and mineral qualities.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
